AI assistant
DEXCOM INC — Director's Dealing 2024
Mar 14, 2024
30198_dirs_2024-03-14_8a879347-3bdd-4088-bfca-0a03a8687241.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2024-03-12
Reporting Person: Sylvain Jereme M (EVP Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-12 | Common Stock | S | 11661 | $134.4107 | Disposed | 85534 | Direct |
Footnotes
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 52,009 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 7,060 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 4,384 of which were granted on December 15, 2021 and shall vest through December 15, 2024.